Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 7/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923969 | 0.91 | MCL1 (0.45) | KLK7FKBP1AABCB1NR1H2NR1H3 | |
| SCHEMBL1781452 | 0.91 | MCL1 (0.45) | KLK7FKBP1AABCB1NR1H2NR1H3 | |
| SCHEMBL1781450 | 0.91 | MCL1 (0.45) | KLK7FKBP1AABCB1NR1H2NR1H3 | |
| SCHEMBL28450753 | 0.86 | FKBP1A (0.47) | KLK7FKBP1ANR1H2NR1H3STS | |
| SCHEMBL16857545 | 0.85 | FKBP1A (0.51) | KLK7FKBP1A | |
| SCHEMBL16857543 | 0.85 | FKBP1A (0.51) | KLK7FKBP1A | |
| SCHEMBL16857540 | 0.85 | FKBP1A (0.51) | KLK7FKBP1A | |
| SCHEMBL22322657 | 0.85 | KLK7 (0.48) | KLK7FKBP1ANR1H2NR1H3STS | |
| SCHEMBL29550939 | 0.85 | KLK7 (0.48) | KLK7FKBP1ANR1H2NR1H3STS | |
| SCHEMBL7149261 | 0.83 | POLB (0.43) | KLK7ABCB1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136591-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | CYTEIR THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| CN-114514023-B | Methods of treating pancreatic cancer using RAD51 inhibitors | 赛泰尔治疗公司 | 2025-01-14 | — | — | CN | disclosed |
| US-12064419-B2 | Methods of using RAD51 inhibitors for treatment of pancreatic cancer | CYTEIR THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-111542521-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3681884-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3986402-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | Cyteir Therapeutics, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220056022-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| CN-111542521-A | RAD51 inhibitors | 赛泰尔治疗公司 | 2020-08-14 | — | — | CN | disclosed |
| US-20190194182-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | RAD51, MRE11, RAD52 | KLK7 2384/4885FKBP1A 2507/4885ABCB1 3189/4885 |
| US-20250136591-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | KLK7 2425/4885FKBP1A 1433/4885ABCB1 3022/4885 |
| US-20220056022-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | KLK7 2425/4885FKBP1A 1433/4885ABCB1 3022/4885 |
| US-20190194182-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | KLK7 2425/4885FKBP1A 1433/4885ABCB1 3022/4885 |
| US-12064419-B2 | Methods of using RAD51 inhibitors for treatment of pancreatic cancer | RAD51, MRE11, RAD52 | KLK7 2384/4885FKBP1A 2507/4885ABCB1 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.